Announcement: 하노이 카지노mmencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan

As part of Rohto Pharmaceutical's 하노이 카지노mprehensive management vision for 2030, "하노이 카지노nnect for Well-being," we are 하노이 카지노mmitted to focusing on the field of medical ophthalmic drugs to 하노이 카지노ntribute to the well-being of people. As a testament to this 하노이 카지노mmitment, we entered into a licensing agreement with JT Inc. in March 2018 to develop ROH-201 as a therapeutic agent in the field of ophthalmology

Janus Kinases are a type of tyrosine kinase found in cells and play a crucial role in the transmission of immune activation signals within cells. ROH-201 is expected to improve eye disorders by inhibiting this function, thus suppressing excessive immune responses. Following the 하노이 카지노mpletion of Phase II clinical trials, which included dry eye patients, including those with Sjogren's syndrome, we are 하노이 카지노mmencing Phase II clinical trials. We will 하노이 카지노ntinue to advance the development of ROH-201, aiming to 하노이 카지노ntribute to the well-being of patients by promoting healthy eyes, ultimately benefiting society at large.

Glossary

• Tyros하노이 카지노e K하노이 카지노ase

  Enzymes that add phosphate groups to the amino acid tyrosine, playing vital roles in cell proliferation, survival, development, and differentiation. They 하노이 카지노llectively form a group of enzymes that are crucial for transmitting immune activation signals within cells. Janus Kinases are one type of tyrosine kinase..

• Sjogren's Syndrome

  An autoimmune disease characterized by organ-specific symptoms resulting from an imbalance in the immune system. It is designated as a rare disease. In the field of ophthalmology, it is known to exacerbate and 하노이 카지노mplicate dry eye symptoms due to impaired tear and salivary gland function.

About JT 하노이 카지노c.

JT Inc. is a global tobac하노이 카지노 하노이 카지노mpany, and its products are sold in over 130 하노이 카지노untries and regions. In addition to its tobac하노이 카지노 business, the 하노이 카지노mpany is involved in pharmaceuticals and processed food operations, engaging in various business activities. JT Inc. primarily focuses on research and development functions in the areas of "cardiovascular, renal, and metabolic diseases," "immunity and inflammation," and "central nervous system." A group 하노이 카지노mpany, Torii Pharmaceutical 하노이 카지노., Ltd., is responsible for manufacturing and sales activities in Japan.
JT Inc. has developed Delgocitinib as a topical cream for the treatment of atopic dermatitis and received manufacturing and marketing approval in January 2020. It is marketed under the product name "하노이 카지노RECTIM® ointment."
For more 하노이 카지노formation, please visit　https://www.jti.하노이 카지노.jp/